Please login to the form below

Not currently logged in

EU patent extension for Pfizer's Lipitor

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor, could be extended by six months due to new paediatric data concerning the treatment

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor (atorvastatin), could be extended by six months due to new paediatric data concerning the treatment.

According to the Financial Times, the extended exclusivity to May 2012 for what is currently the company's largest selling therapy could earn Pfizer $800m.

Pfizer has said it plans to launch a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

The launch would coincide with the expiration of Lipitor's patent, when the opening of the market to generic competition would be expected to have a dramatic effect on the drug's current £11bn annual revenue.

However, Pfizer has requested a supplementary protection certificate across the EU, which would extend the company's control over supplies and pricing of Lipitor a further six months.

The certificate is part of EU regulations designed to encourage paediatric research regarding medicines.

Lipitor is usually prescribed to adults with high levels of cholesterol, however it can be given to children with the condition familial hypercholesterolaemia - a specific type of inherited high cholesterol that runs in the family.

11th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....